These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids. Ziske C; Etzrodt PE; Eliu AS; Gorschlüter M; Strehl J; Flieger D; Messmer D; Schmitz V; Gonzalez-Carmona MA; Sievers E; Brossart P; Sauerbruch T; Schmidt-Wolf IG Pancreas; 2009 Oct; 38(7):758-65. PubMed ID: 19546834 [TBL] [Abstract][Full Text] [Related]
24. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Loskog AS; Fransson ME; Totterman TT Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8816-21. PubMed ID: 16361570 [TBL] [Abstract][Full Text] [Related]
25. Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses. Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M Anticancer Res; 2004; 24(5A):2713-6. PubMed ID: 15517876 [TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Hikosaka S; Hara I; Miyake H; Hara S; Kamidono S Int J Urol; 2004 Aug; 11(8):647-52. PubMed ID: 15285756 [TBL] [Abstract][Full Text] [Related]
27. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. Lindqvist C; Sandin LC; Fransson M; Loskog A J Immunother; 2009 Oct; 32(8):785-92. PubMed ID: 19752755 [TBL] [Abstract][Full Text] [Related]
28. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411 [TBL] [Abstract][Full Text] [Related]
30. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Liu Y; Qureshi M; Xiang J Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168 [TBL] [Abstract][Full Text] [Related]
31. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257 [TBL] [Abstract][Full Text] [Related]
33. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741 [TBL] [Abstract][Full Text] [Related]
35. Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. Iida T; Shiba H; Misawa T; Ohashi T; Eto Y; Yanaga K Surgery; 2010 Nov; 148(5):925-35. PubMed ID: 20378141 [TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496 [TBL] [Abstract][Full Text] [Related]
37. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells. Liu KJ; Lu LF; Cheng HT; Hung YM; Shiou SR; Whang-Peng J; Juang SH Cancer Gene Ther; 2004 Feb; 11(2):135-47. PubMed ID: 14647233 [TBL] [Abstract][Full Text] [Related]
38. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap. Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073 [TBL] [Abstract][Full Text] [Related]
39. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033 [TBL] [Abstract][Full Text] [Related]
40. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]